I know you are but what am I: The Tipline for 19 May 2023

That’s not the worst comeback Mylan Pharmaceuticals could’ve used after being called a monopolist. Less than a year after beating back Sanofi-Aventis’ illegal monopolisation claims about EpiPens, Mylan is going further than playground taunts and accusing the company of nearly identical conduct related to insulin. Also in Tipline, the US Department of Agriculture wants to beef up its toolkit against anticompetitive conduct in the meatpacking industry – but might not get the budget to do so.

Unlock unlimited access to all Global Competition Review content